GSK recall sets Avandia deadline

GPs have until 21 October to take patients off diabetes drug rosiglitazone after manufacturer GSK issued a recall.

GSK has recalled Avandia diabetes drug tablets (Photograph: SPL)

After this date, the rosiglitazone products Avandia and Avandamet will no longer be available in the UK. GSK said that all patients should be switched onto alternative treatments before this date.

A statement from GSK said: ‘In agreement with the MHRA, we believe that a 28-day period from the date of the EMA recommendation will be adequate for patients to be reviewed and transitioned to alternative treatments.’

GPs are advised to review all patients on the drugs as soon as possible and before this deadline.

Prescribers should not issue new or repeat prescriptions of rosiglitazone-containing medicines, said GSK.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

Dr Zoe Norris

GPDF slashes costs and overhauls funding rules to 'restore trust' with GPs

The General Practice Defence Fund (GPDF) has cancelled contracts worth hundreds of...

Churchill Gardens

Scheme from Brazil helps address health inequalities in London practice

A scheme involving community health and wellbeing workers, which is based on a long-standing...

Talking General Practice logo

Podcast: How an initiative from Brazil could help general practice and improve outcomes

Dr Matt Harris and London GP Dr Connie Junghans Minton explain how an initiative...

Medical centre sign

One in three GP practices in Northern Ireland faced serious closure risk in past 18 months

One in three GP practices in Northern Ireland have faced a serious risk of closure...

BMA sign

BMA warns Treasury 'many practices' will close without emergency financial support

GP leaders have urged the Treasury to agree emergency funding to support general...


Practices can use £172m PCN cash to support staff pay rises, GP leaders say

Practices can use their share of Β£172m from the 2023/24 investment and impact fund...